Akums Drugs and Pharmaceuticals shareholding pattern

·Pharma & HealthChart ›

Who owns itSep 2026 quarter

Promoters75.26%no change
Foreign investors (FII)4.50%+2.59 pts
Domestic institutions (DII)11.08%−2.36 pts
of which mutual funds7.58%−2.19 pts
of which insurance companies0.12%
Public6.43%
Others2.73%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹668.50

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹10,235 Cr
Holding % of Total Shares
12 Months Ending
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group75.2675.2675.2675.2675.2675.2675.2675.2675.26
FII / FPI7.346.365.774.242.281.151.371.914.50
DII7.527.007.408.859.2814.4014.3513.4411.08
Mutual Funds5.185.546.116.736.4411.2310.959.777.58
Latest: 2026-09-30 · 10 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.